Skip Navigation



Annals of Oncology Advance Access published online on April 11, 2008
Annals of Oncology, doi:10.1093/annonc/mdn162
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/8/1435    most recent
mdn162v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by de La Motte Rouge, T.
Right arrow Articles by Lhommé, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de La Motte Rouge, T.
Right arrow Articles by Lhommé, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor

T. de La Motte Rouge1, P. Pautier1, P. Duvillard2, A. Rey3, P. Morice4, C. Haie-Meder5, P. Kerbrat6, S. Culine7, F. Troalen2 and C. Lhommé1,*

1 Department of Medical Oncology
2 Department of Biopathology
3 Department of Biostatistics
4 Department of Surgery
5 Department of Radiotherapy, Institut Gustave Roussy, Villejuif
6 Centre Eugène Marquis, Université de Rennes 1, Rennes
7 Centre Régional de Lutte Contre le Cancer Val d'Aurelle, Montpellier, France

* Correspondence to: Dr C. Lhommé, Consultation de gynécologie médicale, Institut Gustave Roussy, 39 rue Camille Desmoulins, F-94800 Villejuif, France. Tel: +33-1-42-11-43-77; Fax: +33-1-42-11-52-14; E-mail: lhomme{at}igr.fr

Background: Ovarian yolk sac tumor (YST) is a very rare malignancy arising in young women. Chemotherapy has dramatically improved the prognosis. Current treatment consists of surgery followed by bleomycin, etoposide, and cisplatin (BEP) chemotherapy. However, given the rarity of this tumor, ovarian YST-specific survival and outcome after such treatment are not precisely known.

Patients and methods: This report concerns prospectively recorded cases that were either treated at Institut Gustave Roussy (Villejuif, France) or referred there for advice about therapy. From 1990 to 2006, 52 patients underwent surgery followed by BEP chemotherapy. Data on patient characteristics, treatment, survival, and fertility outcome were analyzed to assess treatment efficacy and gonadal toxicity after achieving a complete remission.

Results: Thirty-five patients had stage I/II tumors while 17 patients presented with stage III/IV disease. With a median follow-up of 68 months, the overall 5-year survival and disease-free survival rates were 94% and 90%, respectively. Forty-one women underwent fertility-sparing surgery. Pregnancy was achieved in 12 of 16 (75%) women who attempted conception. Overall, 19 pregnancies have been recorded.

Conclusions: BEP chemotherapy following fertility-sparing surgery is a very effective treatment of ovarian YSTs. Most of the patients who attempt conception after complete remission will have children.

alpha-fetoprotein, BEP, endodermal sinus tumor, fertility, malignant ovarian germ-cell tumor

Received for publication November 30, 2007. Revision received February 6, 2008. Accepted for publication March 17, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.